Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan and Fludarabine Conditioning for Allo-SCT in Relapsed/Refractory T- and NK/T-cell Lymphomas
NCT02859402Phase 2Recruiting
- Start
- Dec 2016
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of busulfan, fludarabine in T-cell non-Hodgkin lymphoma, Extranodal NK/T-cell lymphoma (ENKTL). Started Dec 2016; status: recruiting.
02
Drugs
busulfanfludarabine
03
Conditions
T-cell non-Hodgkin lymphomaExtranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT02859402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02859402.